StockNews.AI
CYRX
StockNews.AI
42 days

Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers

1. Cryoport launches next-generation vapor shippers enhancing safety and reliability. 2. New models extend hold times to 19 and 26 days, improving shipment security. 3. Patented technologies reduce shipping damage risks and lower operational costs. 4. Cryoport aims to support advancements in life sciences through enhanced solutions. 5. Upgrades target risks associated with transporting temperature-sensitive biological materials.

9m saved
Insight
Article

FAQ

Why Bullish?

The launch of upgraded products is likely to boost customer interest and revenue, similar to successful product launches by other companies in biotechnology that drove stock prices up. Enhanced shipper reliability can lead to higher market adoption and financial performance.

How important is it?

The product enhancements are directly applicable to CYRX's operations and market positioning, suggesting a strong potential for future revenue growth and market share expansion in the life sciences sector.

Why Long Term?

The improvements in shipping technology will have a sustained positive effect over time as companies increasingly rely on reliable logistics for biological materials. Historical trends show that companies investing in innovative solutions often see stock price growth as market adoption increases.

Related Companies

PFEMRNABNTX
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology , /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures. Built on MVE's legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and 4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments. These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissues materials for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines, while maintaining the materials' integrity throughout the journey. The new SC 4/2V and SC 4/3V vapor shipper models include several key advancements designed to enhance performance and reliability. Hold times for both next-generation models have been significantly extended to up to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days) which provides greater flexibility and security during transit delays. MVE's patented BEND DON'T BREAK™ technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping. "At MVE, we are committed to continuously refining our products to meet the evolving demands of our customers," said Mike Duich, President and CEO of MVE Biological Solutions. "The new SC 4/2V and 4/3V vapor shippers, built on our proven and trusted platform, are now strengthened with longer hold times, reduced refill frequency and lower operating costs.  Additional features of our patent-pending technology also protect against vacuum degradation and absorbs shocks, with the ultimate goal of reducing damage-related failures and costly re-shipments. These enhancements reflect our broader mission to support scientific progress with robust, dependable, and cost-efficient cryogenic systems." Jerrell Shelton, CEO of Cryoport added, "these advances in the SC series of our patented vapor shippers are a part of our ongoing efforts to continually improve our products and services that support our advanced temperature-controlled supply chain solutions for the life sciences. By providing longer temperature hold times, better protection against sudden shock along with additional security features, we have further reduced the supply chain risks for highly valued temperature sensitive life sciences materials which helps with the advancement of the life sciences industry." Other upgraded features of the new vapor shippers include a newly integrated lid locking tab which helps prevent breakage, along with MVE's patent-pending Vapor Shield Technology, which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling. These enhancements work together to provide greater reliability and "peace of mind" when transporting critical biological materials. For more information on the SC 4/2V and SC 4/3V vapor shippers, please visit https://mvebio.com/. About Cryoport, IncCryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™." Our corporate headquarters, located in Nashville, Tennessee, is complemented by global sites in the Americas, EMEA, and APAC. For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates. Forward-Looking StatementsStatements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to MVE Biological Solutions' SC 4/2V and SC 4/3V shippers, including their potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. SOURCE Cryoport, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News